Market Cap | 165.49M | P/E | - | EPS this Y | 19.10% | Ern Qtrly Grth | - |
Income | -64.47M | Forward P/E | -2.78 | EPS next Y | 16.20% | 50D Avg Chg | 1.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 10.00% |
Dividend | N/A | Price/Book | 1.31 | EPS next 5Y | - | 52W High Chg | -61.00% |
Recommedations | 1.60 | Quick Ratio | 7.04 | Shares Outstanding | 15.06M | 52W Low Chg | 289.00% |
Insider Own | 6.15% | ROA | -60.09% | Shares Float | 10.22M | Beta | 2.18 |
Inst Own | 55.97% | ROE | -112.67% | Shares Shorted/Prior | 327.30K/282.04K | Price | 1.50 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 326,524 | Target Price | 67.50 |
Oper. Margin | - | Earnings Date | May 10 | Volume | 207,611 | Change | -1.96% |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and novel conditioning regimens for stem cell transplantation and ex-vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is headquartered in Redwood City, California.
RBC Capital | Outperform | Mar 28, 24 |
TD Cowen | Outperform | Mar 18, 24 |
Oppenheimer | Outperform | Mar 7, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
WIGGANS THOMAS G | Director Director | Nov 16 | Buy | 0.61 | 30,000 | 18,300 | 30,000 | 11/20/23 |
Lis William | Director Director | Oct 13 | Sell | 0.8508 | 7,965 | 6,777 | 53,521 | 10/13/23 |
Mahal Jeetinder Singh | See Remarks See Remarks | Jun 13 | Sell | 1.66 | 9,000 | 14,940 | 287,223 | 06/13/23 |
Mahal Jeetinder Singh | See Remarks See Remarks | Jun 13 | Option | 0.71 | 9,000 | 6,390 | 296,223 | 06/13/23 |
Qiming U.S. Healthcare Fund II... | 10% Owner 10% Owner | Jan 27 | Buy | 1.50 | 2,666,666 | 3,999,999 | 8,519,648 | 04/11/23 |
Carlyle Group Inc. | 10% Owner 10% Owner | Jan 27 | Buy | 1.50 | 3,133,333 | 4,700,000 | 8,761,891 | 01/31/23 |
- | - - | Feb 22 | Sell | 10.48 | 12,810 | 134,249 | 1,050,002 | 02/22/21 |
- | - - | Dec 31 | Sell | 10.25 | 93 | 953 | 1,073,125 | 12/31/20 |
- | - - | Dec 28 | Sell | 10.18 | 20,000 | 203,600 | 1,073,218 | 12/28/20 |
- | - - | Dec 15 | Sell | 10.08 | 20,000 | 201,600 | 1,093,218 | 12/15/20 |
- | - - | Dec 09 | Sell | 10.39 | 12 | 125 | 1,113,218 | 12/09/20 |
- | - - | Dec 09 | Sell | 10.39 | 12 | 125 | 1,113,218 | 12/09/20 |
- | - - | Dec 09 | Sell | 10.39 | 12 | 125 | 1,113,218 | 12/09/20 |
- | - - | Sep 18 | Sell | 10 | 1,020 | 10,200 | 1,114,230 | 09/18/20 |